Everett Collection / Shutterstock.com
HemoShear creates systems for predicting human responses to drugs by applying its proprietary technology to human cells in the lab to make them behave the way they would in vivo. LSIPR found out about its strategy for protecting and developing its technologies.
In the business of drug development, the biggest hurdle to clear is often the jump from pre-clinical testing, where the drug is screened for safety and efficacy in animals, to clinical testing, where it is first introduced into a human.
Many drugs fail at this point in their development but a serendipitous meeting of minds at the University of Virginia has presented a new hope for tackling an age-old problem.
Working models
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
HemoShear; Brian Wamhoff; patent protection;
